The 20 Best Relapsed Refractory Multiple Myeloma (RRMM) Doctors Near Me in Baltimore, MD

Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma. Dr. Huff is board certified in American Board Of Internal Medicine.

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health. Dr. Ali is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Gastrostomy.

Christian Gocke is a Hematologist practicing medicine in Baltimore, Maryland. He has been practicing medicine for over 17 years. Dr. Gocke is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gocke is board certified in American Board Of Internal Medicine.

Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies. Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins. Dr. Imus is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Webster is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Webster has expertise in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Dr. Webster received his medical degree from The Stanford University School of Medicine. He completed residency training in internal medicine at Johns Hopkins followed by a fellowship in medical oncology. He completed the Science of Clinical Investigation curriculum at the Johns Hopkins Bloomberg School of Public health. Dr. Webster is a member of the American Society of Hematology, and the American Society of Clinical Oncology. Dr. Webster’s research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of acute leukemias (ALL and AML). He has specific expertise in the use of maintenance therapies following bone marrow transplantation. He has developed novel clinical trials utilizing immunotherapy for the treatment of ALL and the prevention of post-transplant relapse in both ALL and AML. He serves as the Principal Investigator for these trials of post-transplant maintenance strategies, as well as the site PI for multi-center trials that are currently being conducted through the Eastern Co-operative Oncology Group (ECOG)-ACRIN and Experimental Therapeutics Clinical Trials Network (ETCTN). As the leader of the adult ALL program at Johns Hopkins, he has focused on increasing clinical trial enrollments and improving outcomes in adult ALL. Dr. Webster is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Leukemia, and Bone Marrow Aspiration.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Fuchs is board certified in American Board Of Internal Medicine.

Adam Levin, MD, joined the Johns Hopkins Department of Orthopaedic Surgery as an assistant professor in orthopaedic oncology. Dr. Levin comes to Johns Hopkins after working as an orthopaedic oncologist at the North Shore/LIJ Health System in New York. He completed his residency in orthopaedic surgery at Long Island Jewish Medical Center, and a fellowship in orthopaedic oncology at the Memorial Sloan-Kettering Cancer Center. Dr. Levin offers care and consultations for adults and children with bone and soft tissue tumors of the pelvis and extremities. He has extensive experience in performing limb-sparing and complex extremity reconstruction surgeries. Dr. Levin has a special interest in surgical palliation and biologic reconstruction. Dr. Levin is a member of the American Academy of Orthopaedic Surgeons and the Musculoskeletal Tumor Society. Dr. Levin is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Metachondromatosis, Maffucci Syndrome, Ollier Disease, Hip Replacement, and Bone Marrow Aspiration. Dr. Levin is board certified in American Board Of Orthopaedic Surgery.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS). Dr. Jones is board certified in American Board Of Internal Medicine.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine.

William Houck is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 73 other conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Houck is board certified in American Board Of Internal Medicine.

Mehmet Kocoglu is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Kocoglu is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Ashraf Badros is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Badros is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Plasmacytoma, and Bone Marrow Transplant.

Dr. Cheng Ting Lin is an associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine. His expertise is in diagnostic radiology with particular focus on chest and cardiac imaging. Dr. Cheng Ting Lin received his undergraduate degree from Boston University. He graduated from State University of New York at Stony Brook, where he also completed a radiology residency training program. Dr. Lin completed fellowship training in cardiothoracic imaging at University of Maryland Medical Center. His research interest includes lung cancer screening and diagnosis, chronic obstructive pulmonary disease, Interstitial lung disease, pulmonary embolism, and coronary artery disease. Dr. Lin is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Lung Nodules, Interstitial Lung Disease, Pulmonary Arteriovenous Fistula, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Lin is board certified in American Board Of Radiology.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Garg is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 58 other conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura. Dr. Garg is board certified in American Board Of Internal Medicine.

As a member of the Johns Hopkins Kimmel Cancer Center, my group's research is focused on finding novel therapies for the treatment of both acute and chronic graft versus host disease (GVHD). To that end, we are developing new strategies for prophylaxis as well as therapies for this problem. We are exploring the use of drugs such as pentostatin in steroid refractory GVHD. This drug inhibits an enzyme, called ADA, that induces apoptosis (cell death) of lymphocytes, the effector cells in GVHD. Our results using this approach have been quite encouraging. Also, we are exploring other novel approaches such as extracorporeal photopheresis or high-dose cyclophosphamide. We are participating in the NIH Bone Marrow Transplant Clinical Trials Network consortium to find useful therapies for GVHD. We are also members of the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials on Chronic GVHD, and there we are trying to establish rational guidelines for supportive care, trial design, etc. We run an internationally unique GVHD multidisciplinary clinic with many GVHD experts including a nurse practitioner, research nurse and others from fields such as physical medicine and rehabilitation, gastroenterology, ophthalmology, dermatology, pulmonology and more. Dr. Meade is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Robert Benitez is a Cardiologist practicing medicine in Baltimore, Maryland. Dr. Benitez is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Necrosis, Cardiogenic Shock, Mitral Valve Regurgitation, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

Aaron Rapoport is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Rapoport is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Nancy Hardy is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Hardy is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Djordje Atanackovic is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Atanackovic is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.